Masimo

Masimo (Nasdaq: MASI) reported third-quarter results that beat the consensus forecast on Wall Street — but it held down its Q4 guidance.

“We delivered strong results in the third quarter, with revenue and earnings exceeding expectations. Our healthcare segment achieved double-digit constant currency growth, and our consumer non-healthcare segment reported another quarter of better-than-expected results. Our performance in the third quarter was achieved in a challenging environment and made possible by commendable contributions from our entire team,” CEO Joe Kiani said in a news release yesterday evening.

The Irvine, California–based maker of health monitoring tech and high-end sound systems earned $37.9 million, or 70¢ per share, off $549.3 million for the quarter that ended Oct. 1, 2022. The bottom line was down by more than a third, while the top line was up by nearly 79% compared with Q3 2021.

Healthcare revenue was $327.2 million, up 6.4%. Non-…

[Image from Masimo]Masimo (Nasdaq:MASI) announced today that it began the full market release of its Masimo W1 health watch for consumer use.

Irvine, California-based Masimo designed its W1 watch to offer accurate, continuous measurements and insightful health data. The wrist-worn wearable builds on the company’s personal, lifestyle-friendly designs for non-invasive blood parameter monitoring solutions.

For the first time in a watch format, the company said, W1 provides accurate, continuous monitoring of oxygen saturation (SpO2). It also provides pulse rate, respiration rate and more measurements. In a limited market release, the Masimo W1 offers hydration index measurements.

The device takes 86,400 measurements a day for second-by-second data trending. It pairs through secure Bluetooth to the Masimo Health smartphone app.

Masimo launched the Personal SafetyNet alongside the watch. Personal SafetyNet, a paid subscription service within the comp…

Masimo (Nasdaq: MASI) posted second-quarter results today that beat the consensus forecast on Wall Street.

The Irvine, California-based patient monitoring tech company reported profits of $18.1 million, or $0.33 per diluted share, on sales of $565.3 million for the three months ended July 2, 2022, for a bottom-line decrease of 64% and sales growth of 85.3% compared with Q2 2021.

Adjusted to exclude one-time items, earnings per share were $1.35, $0.15 ahead of the Street, where analysts were looking for EPS of $1.20 on sales of $540.6 million.

“Our healthcare business fulfilled most of the delayed shipments from the first quarter by increasing manufacturing output, which boosted our growth in the second quarter. As a result, our healthcare business delivered 11% constant currency revenue growth for the first half of the year,” Masimo CEO and Chair Joe Kiani said in a news release.

Masimo said it expects to log adjusted EPS of $4.34 to $4.57 t…

[Image from Masimo]Masimo (Nasdaq:MASI) announced today that the findings of a trial support the use of its SedLine brain function monitoring.

Results from the randomized, controlled trial were published in the Journal of Clinical Anesthesia. In the trial, Dr. Melody H.Y. Long and colleagues from the KK Women’s and Children’s Hospital in Singapore evaluated the ability of electroencephalogram (EEG)-guided anesthesia, using Masimo SedLine brain function monitoring, to reduce the amount of the drug sevoflurane needed to maintain anesthesia in pediatric patients undergoing minor surgery.

The study demonstrated that use of SedLine to guide anesthesia reduced sevoflurane requirements and led to a reduced incidence of burst suppression, which has previously been reported to be associated with postoperative delirium.

Masimo said in a news release that the study enrolled 195 children between age one and six who were scheduled for minor surgery involving general ane…

Masimo CEO Joe Kiani [Image courtesy of Masimo]Masimo (Nasdaq: MASI) shareholders recently voted to advise against the company’s compensation package for top executives.

About 52.6% of voting shareholders voted against the patient monitoring tech company’s handling of executive pay in what’s known as the Say-on-Pay vote, according to vote results of the May 26 meeting filed with the SEC yesterday. The vote comes on the heels of Say-on-Pay votes at Zimmer Biomet and Henry Schein in which support from investors was lackluster.

In fact, dozens of major U.S. companies — including JPMorgan, Intel and Coca-Cola — have faced shareholder rebukes over executive pay this year, according to a report from The Wall Street Journal. The newspaper cited the trend as part of an overall increase in investor scrutiny of corporate governance — as well as social and environmental issues.

A Masimo spokesperson could not be immediately reached for comment.

Because th…

Former professional tennis player Tommy Haas said the Masimo W1 health watch provides a convenient way to continuously track vitals. [Image courtesy of Masimo]Masimo (Nasdaq: MASI) today announced that it will make its much-anticipated W1 health watch available to 10,000 early adopters.

The select group can buy the W1s on a first-come, first-served basis at a 50% discount, according to Masimo. The goal is to collect feedback from the early adopters as the Irvine, California–based company better refines the digital health product.

The W1 measures multiple health parameters, including oxygen saturation, pulse rate, perfusion index, pleth variability index (PVi) and respiration rate. It also provides step count and fall detection. The watch pairs via secure Bluetooth to the Masimo Personal Health smartphone app.

“I’ve always believed in the power of data to improve my performance. Accurate vital sign measurements have helped me track my activity and recovery b…

[Image from Masimo]Masimo (Nasdaq:MASI) announced today that a retrospective study backed the use of its SedLine brain function monitoring system.

Irvine, California-based Masimo’s study investigated the impact of anesthesia during cardiac surgery guided by SedLine monitoring. The company published the findings in the Journal of Cardiothoracic and Vascular Anesthesia.

According to a news release, Dr. André Denault and colleagues at the Montreal Heart Institute and Centre Hospitalier de l’Université de Montréal studied the use of SedLine’s processed electroencephalography (pEEG) feature, the Patient State Index (PSi). Masimo said the study is the first to primarily explore the impact of pEEG-guided anesthesia on vasoactive and inotropic drugs.

The study’s findings demonstrated that pEEG-guided anesthesia was associated with a reduction in the use of such drugs along with less use of anesthetic agents and opioids in the OR. It also led to lo…